COVID19 impact on the drug manufacturing in India
Loading player...
Investec India hosted Mr Sanjeev Jain (Promoter, Akums Drugs & Pharma – Largest Branded Formulation Contract Manufacturer for Domestic Market) . Mr Jain spoke about the various trends like the demand for GP type medicines like paracetamol and crocin falling amid the COVID19 crisis, whereas diabetic, cardiac and CNS medicines seeing a regular demand, the growth of generic-generic medicines in India and behavioural changes among the patients who are scared to go to doctors, and docs themselves are grappling about opening their clinic with proper protocols.
Mr. Jain is the co-founder & the director of Akums Drugs & Pharma Ltd and has 25+ years of experience in the pharma industry. Akums is India’s single largest Contract Research and Manufacturing (CRAMS) organization responsible for manufacturing approximately 11-12 % of all drugs consumed in the country. It has 9 manufacturing facilities across India and has an annual turnover of ~INR 30 bn.
Mr. Jain is the co-founder & the director of Akums Drugs & Pharma Ltd and has 25+ years of experience in the pharma industry. Akums is India’s single largest Contract Research and Manufacturing (CRAMS) organization responsible for manufacturing approximately 11-12 % of all drugs consumed in the country. It has 9 manufacturing facilities across India and has an annual turnover of ~INR 30 bn.
